Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

A lymphocyte, specific technology, applied in the field of clinical medicine, can solve problems such as no cure

Inactive Publication Date: 2005-12-21
U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These results imply that M1SHMC prolongs survival but does not cure NOD SCID mice with hypertrophic palpable adenocarcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0109] Clinical steps to activate and harvest activated T lymphocytes

[0110] Standard Operating Procedures for Generating CTLs

[0111] Day 0: Samples contained in patient's aphoresis bag and name tag and jumbo label sealed tubes are received from Coffee Blood Center. It was released into a knob cap vial for CBC (Complete Cell Count) on HCC. The volume of the apheresis bag is noted. Attach the patient's label to the culture bag and mark it as Trial #-Patient #-Apheresis Bag 4. The logbook for each patient begins with the first aphoresis. All relevant data, information and results obtained in the laboratory are recorded in this book.

[0112]Incubate sufficient AIM-V medium in a 2-3 liter water bath at 37°C. Use otily fresh unopened bottle. Once opened, that bottle is designated for that patient only. To facilitate removal of the apheresis product from the apheresis bag, the volume of the apheresis bag was subtracted from 1000 ml, and such ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This paper discloses methods for detecting and localizing cell-specific antigens in mammals such as humans, including exposing mammalian peripheral blood mononuclear cells (PBMCs) to antigen-specific immunization under conditions of antigen-specific activation of T lymphocytes in PBMCs. antigenic peptide epitopes, thereby generating at least antigen-specific T lymphocytes that bind to the cell-specific antigen. Labeled antigen-specific T lymphocytes are administered intraperitoneally or intravenously to mammals, usually in the absence of IL-2. The distribution of these cells in mammals is determined by imaging, allowing detection and localization of cell-specific epitopes in mammals. Exposure of PBMCs to immunogenic peptides generally involves cell-free peptide preparations and interleukin-2 (IL-2), but not other cells such as antigen-presenting cells (APCs) that are independently activated by antigen. Antigen-specific T lymphocytes can typically lyse cells expressing the cell-specific antigen and may include CD4+, CD8+ and / or CD45RO+ memory T cells.

Description

[0001] This application claims the benefit of US Provisional Patent Application No. 60 / 417,303, filed October 10, 2002, which is hereby incorporated by reference in its entirety for all purposes. field of invention [0002] The present invention belongs to the field of clinical medicine including diagnosis and treatment. The present invention relates to the use of activated lymphocytes directed against cell-specific antigens such as tumor-specific epitopes, their ability to migrate and attach to tumor epitopes to which they have been sensitized, these cells to amplify localization signals for very small tumors and their use in identifying unknown primary tumors (especially mucin-producing adenocarcinomas) with known immunogenic epitopes. Background of the invention [0003] Methods for imaging tissues such as lymphoid tissue in intact humans using various imaging agents or antibodies are known. For example, U.S. Patent 4,735,210, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/12G01N33/50
CPCA61K51/1203G01N33/5091G01N2800/52
Inventor C·A·菲利普斯S·E·赖特
Owner U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com